ABEO — Abeona Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $244.74m
- $73.37m
- $5.82m
Annual cashflow statement for Abeona Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -84.9 | -39.7 | -54.2 | -63.7 | 71.2 |
| Depreciation | |||||
| Non-Cash Items | 34.3 | -0.988 | 16.7 | 10.1 | -145 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -18.3 | -5.89 | -1.79 | -4.38 | -5.39 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -65.7 | -43.5 | -37 | -56 | -76.3 |
| Capital Expenditures | -4.15 | -0.13 | -0.331 | -2.45 | -7.97 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 70.2 | -23.8 | 0.539 | -36.8 | 113 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 66.1 | -24 | 0.208 | -39.2 | 105 |
| Financing Cash Flow Items | — | — | -0.15 | -0.963 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 24.9 | 43.2 | 37.1 | 104 | 26 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 25.3 | -24.3 | 0.256 | 8.88 | 54.7 |